Alisertib impairs the stemness of hepatocellular carcinoma by inhibiting purine synthesis
Journal of Biological Chemistry · 2025
DOI: 10.1016/j.jbc.2025.108558 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2025. Verfasst von Zhuoran Qi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, China; Shanghai Institute of Liver Diseases, Zhongshan…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Purines, Pyrimidines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hepatocellular carcinoma tumor-repopulating cells (HCC-TRCs) drive disease progression, yet their purine metabolism mechanisms remain poorly understood. This study revealed that the stemness index, strongly linked to poor HCC prognosis, exhibited a robust positive correlation with purine metabolism through single-sample gene set enrichment analysis. Integrated drug screening across CTRP, GDSC, and PRISM databases identified alisertib, an aurora kinase A (AURKA) inhibitor, as a potent agent targeting stemness. Using fibrin gel-based 3D-cultured HCC-TRCs, mechanistic studies demonstrated that alisertib suppresses xanthine and hypoxanthine production by inhibiting the AURKA-AKT signaling axis. This disruption markedly impaired tumor spheroid formation, migration, and invasion in vitro, while significantly suppressed tumor growth in vivo, which could be rescued by the AKT agonist SC79. Our findings revealed a novel therapeutic strategy targeting purine metabolism through AURKA-AKT axis inhibition, effectively eliminating HCC-TRCs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, China; Shanghai Institute of Liver Diseases, Zhongshan Hospital, Fudan University, Shanghai, China.
- Huashan Hospital, Fudan University, Shanghai, China.
- Shanghai Institute of Liver Diseases, Zhongshan Hospital, Fudan University, Shanghai, China.
- Department of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
- Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, China; Shanghai Institute of Liver Diseases, Zhongshan Hospital, Fudan University, Shanghai, China. Electronic address: shen…
- Endoscopy Center, Department of Gastroenterology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China. Electronic address: wzmudxj@163.com.
Zitieren
APA
Qi, Z., Luo, J., Liu, W., Xu, Y., Ma, Y., Hu, S., Shen, X., Du, X., & Xiang, W. (2025). Alisertib impairs the stemness of hepatocellular carcinoma by inhibiting purine synthesis. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2025.108558
Vancouver
Qi Z, Luo J, Liu W, Xu Y, Ma Y, Hu S, et al. Alisertib impairs the stemness of hepatocellular carcinoma by inhibiting purine synthesis. Journal of Biological Chemistry. 2025. doi:10.1016/j.jbc.2025.108558
BibTeX
@article{Qi2025,
author = {Qi, Zhuoran and Luo, Jie and Liu, Wenfeng and Xu, Ye and Ma, Yifan and Hu, Sunkuan and Shen, Xizhong and Du, Xiaojing and Xiang, Wei},
title = {Alisertib impairs the stemness of hepatocellular carcinoma by inhibiting purine synthesis},
journal = {Journal of Biological Chemistry},
year = {2025},
doi = {10.1016/j.jbc.2025.108558}
}
EUVIMED